Table 2. Characteristics of patient with and without PCa in the training cohort.
| Variables | Non-PCa (n=65) | PCa (n=178) | P value |
|---|---|---|---|
| Age (years) | 67.00 (59.00, 71.00) | 71.00 (67.00, 77.00) | <0.001* |
| tPSA (ng/mL) | 11.32 (7.76, 16.72) | 16.23 (9.29, 39.48) | <0.001* |
| fPSA (ng/mL) | 1.66 (1.07, 2.36) | 2.06 (1.36, 4.82) | 0.001* |
| f/t PSA | 0.14 (0.11, 0.22) | 0.13 (0.10, 0.17) | 0.203 |
| ADC (×10−6 mm2/s) | 1,111.03 (974.89, 1,350.59) | 857.06 (773.51, 961.95) | <0.001* |
| T1 (msec) | 1,353.87 (1,236.63, 1,563.08) | 1,263.37 (1,206.96, 1,340.17) | <0.001* |
| T2 (msec) | 93.28 (83.91, 101.70) | 81.48 (77.01, 87.37) | <0.001* |
| PD (pu) | 82.59 (81.29, 83.94) | 81.02 (79.71, 82.50) | <0.001* |
| PI-RADS | <0.001* | ||
| PI-RADS 3 | 45 (69.2) | 15 (8.4) | |
| PI-RADS 4 | 13 (20.0) | 46 (25.8) | |
| PI-RADS 5 | 7 (10.8) | 117 (65.7) |
Data were expressed as median (first quartile, third quartile) or number (percentage). *, statistically significant. PCa, prostate cancer; tPSA, total prostate-specific antigen; fPSA, free prostate-specific antigen; f/t PSA, free/total prostate-specific antigen ratio; ADC, apparent diffusion coefficient; T1, longitudinal relaxation time; T2, transverse relaxation time; PD, proton density; PI-RADS, Prostate Imaging-Reporting and Data System.